Bruce A Reitz
Publication Details
-
Leflunomide prolongs pulmonary allograft and xenograft survival.
J Heart Lung Transplant. 1995 Nov-Dec; (6 Pt 1): 1136-44
Leflunomide, an isoxazole derivative, has been shown to effectively prolong rodent allograft and cardiac xenograft survival. In vitro studies suggest that leflunomide inhibits the production of donor-specific antibodies and is capable of blocking both T- and B-cell proliferation. In light of the significant role that humoral immunity is believed to play in chronic pulmonary allograft rejection as well as hyperacute and accelerated acute xenograft rejection, we examined the efficacy of leflunomide in prolonging pulmonary allografts and xenografts and its effect on donor-specific antibody production.
Help